JPH08507767A - 管脈形成を抑制する方法および組成物 - Google Patents

管脈形成を抑制する方法および組成物

Info

Publication number: JPH08507767A
Authority: JP; Japan
Prior art keywords: angiogenesis; compound; human; group; animal
Prior art date: 1993-03-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

JP6520046A

Other languages

English (en)

Japanese (ja)

Inventor

ダマト，ロバート

Original Assignee

ザ・チルドレンズ・メデイカル・センター・コーポレーシヨン

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-03-01

Filing date

1994-02-24

Publication date

1996-08-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26699202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH08507767(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-02-24 Application filed by ザ・チルドレンズ・メデイカル・センター・コーポレーシヨン filed Critical ザ・チルドレンズ・メデイカル・センター・コーポレーシヨン

1996-08-20 Publication of JPH08507767A publication Critical patent/JPH08507767A/ja

Status Withdrawn legal-status Critical Current

Links

230000033115 angiogenesis Effects 0.000 title claims abstract description 88
238000000034 method Methods 0.000 title claims description 87
239000000203 mixture Substances 0.000 title claims description 64
230000002401 inhibitory effect Effects 0.000 title claims description 13
150000001875 compounds Chemical class 0.000 claims abstract description 102
UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims abstract description 25
229960003433 thalidomide Drugs 0.000 claims abstract description 23
-1 analogs Substances 0.000 claims abstract description 11
241001465754 Metazoa Species 0.000 claims description 43
239000004037 angiogenesis inhibitor Substances 0.000 claims description 17
150000002118 epoxides Chemical group 0.000 claims description 15
229940122183 Epoxide hydrolase inhibitor Drugs 0.000 claims description 14
230000015572 biosynthetic process Effects 0.000 claims description 13
229940121369 angiogenesis inhibitor Drugs 0.000 claims description 11
230000002491 angiogenic effect Effects 0.000 claims description 11
150000001336 alkenes Chemical class 0.000 claims description 9
150000001345 alkine derivatives Chemical class 0.000 claims description 9
125000004122 cyclic group Chemical group 0.000 claims description 9
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 8
208000005590 Choroidal Neovascularization Diseases 0.000 claims description 8
206010060823 Choroidal neovascularisation Diseases 0.000 claims description 8
208000007135 Retinal Neovascularization Diseases 0.000 claims description 8
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 8
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 8
239000003795 chemical substances by application Substances 0.000 claims description 8
201000000159 corneal neovascularization Diseases 0.000 claims description 8
230000002207 retinal effect Effects 0.000 claims description 8
VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims description 7
FEFFSKLJNYRHQN-UHFFFAOYSA-N 2-Phthalimidoglutaricacid Chemical compound C1=CC=C2C(=O)N(C(CCC(=O)O)C(O)=O)C(=O)C2=C1 FEFFSKLJNYRHQN-UHFFFAOYSA-N 0.000 claims description 7
206010012689 Diabetic retinopathy Diseases 0.000 claims description 7
208000002780 macular degeneration Diseases 0.000 claims description 7
231100000378 teratogenic Toxicity 0.000 claims description 7
230000003390 teratogenic effect Effects 0.000 claims description 7
206010055665 Corneal neovascularisation Diseases 0.000 claims description 6
125000002015 acyclic group Chemical group 0.000 claims description 6
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 6
229910052739 hydrogen Inorganic materials 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 4
231100000816 toxic dose Toxicity 0.000 claims description 4
JGTUBTJLRQIMAB-UHFFFAOYSA-N 4-chloro-3,5-dimethyl-1h-pyrazole Chemical compound CC1=NNC(C)=C1Cl JGTUBTJLRQIMAB-UHFFFAOYSA-N 0.000 claims description 3
150000001299 aldehydes Chemical class 0.000 claims description 3
150000001335 aliphatic alkanes Chemical class 0.000 claims description 3
125000000217 alkyl group Chemical group 0.000 claims description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
125000004432 carbon atom Chemical group C* 0.000 claims description 3
150000001924 cycloalkanes Chemical class 0.000 claims description 3
150000002148 esters Chemical class 0.000 claims description 3
125000001033 ether group Chemical group 0.000 claims description 3
229910052736 halogen Inorganic materials 0.000 claims description 3
150000002367 halogens Chemical class 0.000 claims description 3
239000001257 hydrogen Substances 0.000 claims description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
150000003949 imides Chemical group 0.000 claims description 3
150000002576 ketones Chemical class 0.000 claims description 3
229910052757 nitrogen Inorganic materials 0.000 claims description 3
229910052698 phosphorus Inorganic materials 0.000 claims description 3
125000005544 phthalimido group Chemical group 0.000 claims description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
229910052717 sulfur Inorganic materials 0.000 claims description 3
150000001298 alcohols Chemical class 0.000 claims description 2
150000001735 carboxylic acids Chemical class 0.000 claims description 2
230000005764 inhibitory process Effects 0.000 abstract description 8
239000002207 metabolite Substances 0.000 abstract description 3
239000002243 precursor Substances 0.000 abstract description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 46
201000010099 disease Diseases 0.000 description 43
206010028980 Neoplasm Diseases 0.000 description 24
210000004204 blood vessel Anatomy 0.000 description 16
241000283973 Oryctolagus cuniculus Species 0.000 description 12
208000015181 infectious disease Diseases 0.000 description 11
208000014674 injury Diseases 0.000 description 11
210000004087 cornea Anatomy 0.000 description 10
230000006378 damage Effects 0.000 description 10
238000011282 treatment Methods 0.000 description 10
238000003556 assay Methods 0.000 description 9
241000282412 Homo Species 0.000 description 8
239000004480 active ingredient Substances 0.000 description 8
208000017442 Retinal disease Diseases 0.000 description 7
206010038923 Retinopathy Diseases 0.000 description 7
208000025865 Ulcer Diseases 0.000 description 7
230000001684 chronic effect Effects 0.000 description 7
210000002889 endothelial cell Anatomy 0.000 description 7
201000011066 hemangioma Diseases 0.000 description 7
239000000843 powder Substances 0.000 description 7
230000008733 trauma Effects 0.000 description 7
231100000397 ulcer Toxicity 0.000 description 7
239000003814 drug Substances 0.000 description 6
230000000694 effects Effects 0.000 description 6
206010023332 keratitis Diseases 0.000 description 6
239000007788 liquid Substances 0.000 description 6
206010039073 rheumatoid arthritis Diseases 0.000 description 6
208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 description 5
206010027476 Metastases Diseases 0.000 description 5
206010029113 Neovascularisation Diseases 0.000 description 5
208000027418 Wounds and injury Diseases 0.000 description 5
230000001772 anti-angiogenic effect Effects 0.000 description 5
229940079593 drug Drugs 0.000 description 5
230000012010 growth Effects 0.000 description 5
206010025135 lupus erythematosus Diseases 0.000 description 5
230000002265 prevention Effects 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
206010052779 Transplant rejections Diseases 0.000 description 4
NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 4
230000002159 abnormal effect Effects 0.000 description 4
239000002253 acid Substances 0.000 description 4
210000002469 basement membrane Anatomy 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
210000000845 cartilage Anatomy 0.000 description 4
238000002513 implantation Methods 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
230000009401 metastasis Effects 0.000 description 4
230000001575 pathological effect Effects 0.000 description 4
239000008188 pellet Substances 0.000 description 4
230000002062 proliferating effect Effects 0.000 description 4
201000000306 sarcoidosis Diseases 0.000 description 4
239000000725 suspension Substances 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
208000006379 syphilis Diseases 0.000 description 4
239000003826 tablet Substances 0.000 description 4
230000000699 topical effect Effects 0.000 description 4
230000029663 wound healing Effects 0.000 description 4
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
229940127514 Epoxide Hydrolase Inhibitors Drugs 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 3
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
208000007766 Kaposi sarcoma Diseases 0.000 description 3
206010025412 Macular dystrophy congenital Diseases 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
206010046851 Uveitis Diseases 0.000 description 3
230000005856 abnormality Effects 0.000 description 3
230000007850 degeneration Effects 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
NGGMYCMLYOUNGM-CSDLUJIJSA-N fumagillin Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)C[C@@]21CO2 NGGMYCMLYOUNGM-CSDLUJIJSA-N 0.000 description 3
230000002538 fungal effect Effects 0.000 description 3
239000008187 granular material Substances 0.000 description 3
208000032839 leukemia Diseases 0.000 description 3
210000003491 skin Anatomy 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
238000011200 topical administration Methods 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
230000002792 vascular Effects 0.000 description 3
230000007998 vessel formation Effects 0.000 description 3
201000007790 vitelliform macular dystrophy Diseases 0.000 description 3
NGGMYCMLYOUNGM-UHFFFAOYSA-N (-)-fumagillin Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)C=CC=CC=CC=CC(O)=O)CCC21CO2 NGGMYCMLYOUNGM-UHFFFAOYSA-N 0.000 description 2
QIWKCQDJZPRXNS-VIFPVBQESA-N (2s)-2-[(2-carboxybenzoyl)amino]pentanedioic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)C1=CC=CC=C1C(O)=O QIWKCQDJZPRXNS-VIFPVBQESA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
241000220479 Acacia Species 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
206010003645 Atopy Diseases 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
206010048964 Carotid artery occlusion Diseases 0.000 description 2
208000009043 Chemical Burns Diseases 0.000 description 2
208000002691 Choroiditis Diseases 0.000 description 2
208000017667 Chronic Disease Diseases 0.000 description 2
208000011231 Crohn disease Diseases 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000005486 Epoxide hydrolase Human genes 0.000 description 2
108020002908 Epoxide hydrolase Proteins 0.000 description 2
208000010412 Glaucoma Diseases 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
208000009889 Herpes Simplex Diseases 0.000 description 2
208000007514 Herpes zoster Diseases 0.000 description 2
206010051151 Hyperviscosity syndrome Diseases 0.000 description 2
102000006992 Interferon-alpha Human genes 0.000 description 2
108010047761 Interferon-alpha Proteins 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
208000016604 Lyme disease Diseases 0.000 description 2
206010029260 Neuroblastoma Diseases 0.000 description 2
208000010191 Osteitis Deformans Diseases 0.000 description 2
208000027868 Paget disease Diseases 0.000 description 2
241001111421 Pannus Species 0.000 description 2
208000003971 Posterior uveitis Diseases 0.000 description 2
206010038910 Retinitis Diseases 0.000 description 2
206010039705 Scleritis Diseases 0.000 description 2
208000021386 Sjogren Syndrome Diseases 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
201000005485 Toxoplasmosis Diseases 0.000 description 2
206010053648 Vascular occlusion Diseases 0.000 description 2
208000010011 Vitamin A Deficiency Diseases 0.000 description 2
206010047663 Vitritis Diseases 0.000 description 2
238000000540 analysis of variance Methods 0.000 description 2
239000002870 angiogenesis inducing agent Substances 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
210000000625 blastula Anatomy 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
239000006071 cream Substances 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
230000001497 fibrovascular Effects 0.000 description 2
229960000936 fumagillin Drugs 0.000 description 2
239000000499 gel Substances 0.000 description 2
208000013653 hyalitis Diseases 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
229940079322 interferon Drugs 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
230000009545 invasion Effects 0.000 description 2
201000010666 keratoconjunctivitis Diseases 0.000 description 2
230000035984 keratolysis Effects 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
208000027202 mammary Paget disease Diseases 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000000465 moulding Methods 0.000 description 2
208000001491 myopia Diseases 0.000 description 2
230000004379 myopia Effects 0.000 description 2
201000003142 neovascular glaucoma Diseases 0.000 description 2
239000002674 ointment Substances 0.000 description 2
230000016087 ovulation Effects 0.000 description 2
239000006072 paste Substances 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
208000028172 protozoa infectious disease Diseases 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
239000003642 reactive oxygen metabolite Substances 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
208000007056 sickle cell anemia Diseases 0.000 description 2
239000000021 stimulant Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 2
229960004291 sucralfate Drugs 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
229960000604 valproic acid Drugs 0.000 description 2
208000021331 vascular occlusion disease Diseases 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
208000016261 weight loss Diseases 0.000 description 2
230000004580 weight loss Effects 0.000 description 2
RFWFOJDAIRDAPK-VKHMYHEASA-N (3s)-3-aminooxane-2,6-dione Chemical compound N[C@H]1CCC(=O)OC1=O RFWFOJDAIRDAPK-VKHMYHEASA-N 0.000 description 1
QQWLXNMPPFCVCD-UHFFFAOYSA-N 1,1-dioxo-2-(2-oxopiperidin-3-yl)-1,2-benzothiazol-3-one Chemical compound O=S1(=O)C2=CC=CC=C2C(=O)N1C1CCCNC1=O QQWLXNMPPFCVCD-UHFFFAOYSA-N 0.000 description 1
CWJJAFQCTXFSTA-UHFFFAOYSA-N 4-methylphthalic acid Chemical group CC1=CC=C(C(O)=O)C(C(O)=O)=C1 CWJJAFQCTXFSTA-UHFFFAOYSA-N 0.000 description 1
102100028187 ATP-binding cassette sub-family C member 6 Human genes 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
206010001257 Adenoviral conjunctivitis Diseases 0.000 description 1
201000000736 Amenorrhea Diseases 0.000 description 1
206010001928 Amenorrhoea Diseases 0.000 description 1
208000031104 Arterial Occlusive disease Diseases 0.000 description 1
206010003226 Arteriovenous fistula Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
206010044583 Bartonella Infections Diseases 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
206010006895 Cachexia Diseases 0.000 description 1
241000282461 Canis lupus Species 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
206010012667 Diabetic glaucoma Diseases 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
208000006168 Ewing Sarcoma Diseases 0.000 description 1
206010063560 Excessive granulation tissue Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
201000002563 Histoplasmosis Diseases 0.000 description 1
101001054334 Homo sapiens Interferon beta Proteins 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
102000003996 Interferon-beta Human genes 0.000 description 1
108090000467 Interferon-beta Proteins 0.000 description 1
SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
206010023203 Joint destruction Diseases 0.000 description 1
208000001126 Keratosis Diseases 0.000 description 1
206010024229 Leprosy Diseases 0.000 description 1
241001467578 Microbacterium Species 0.000 description 1
208000005890 Neuroma Diseases 0.000 description 1
MSHZHSPISPJWHW-PVDLLORBSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)NC(=O)CCl)C[C@@]21CO2 MSHZHSPISPJWHW-PVDLLORBSA-N 0.000 description 1
208000001388 Opportunistic Infections Diseases 0.000 description 1
208000012868 Overgrowth Diseases 0.000 description 1
241000282376 Panthera tigris Species 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
208000004788 Pars Planitis Diseases 0.000 description 1
208000034038 Pathologic Neovascularization Diseases 0.000 description 1
102000007327 Protamines Human genes 0.000 description 1
108010007568 Protamines Proteins 0.000 description 1
201000004613 Pseudoxanthoma elasticum Diseases 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
201000002154 Pterygium Diseases 0.000 description 1
206010037649 Pyogenic granuloma Diseases 0.000 description 1
206010038848 Retinal detachment Diseases 0.000 description 1
201000000582 Retinoblastoma Diseases 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
206010041101 Small intestinal obstruction Diseases 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
206010043275 Teratogenicity Diseases 0.000 description 1
208000018656 Terrien marginal degeneration Diseases 0.000 description 1
229920002807 Thiomer Polymers 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
229960000571 acetazolamide Drugs 0.000 description 1
206010000496 acne Diseases 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
206010064930 age-related macular degeneration Diseases 0.000 description 1
231100000540 amenorrhea Toxicity 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
230000000964 angiostatic effect Effects 0.000 description 1
230000002547 anomalous effect Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
208000021328 arterial occlusion Diseases 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
206010004145 bartonellosis Diseases 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
208000015294 blood coagulation disease Diseases 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000001775 bruch membrane Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
150000001661 cadmium Chemical class 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
210000001612 chondrocyte Anatomy 0.000 description 1
210000003711 chorioallantoic membrane Anatomy 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
210000000078 claw Anatomy 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
210000001520 comb Anatomy 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
229920006237 degradable polymer Polymers 0.000 description 1
210000004207 dermis Anatomy 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
231100000294 dose-dependent toxicity Toxicity 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
210000004177 elastic tissue Anatomy 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
210000004696 endometrium Anatomy 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
208000021373 epidemic keratoconjunctivitis Diseases 0.000 description 1
208000001780 epistaxis Diseases 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
208000030533 eye disease Diseases 0.000 description 1
230000004720 fertilization Effects 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
208000030304 gastrointestinal bleeding Diseases 0.000 description 1
238000007429 general method Methods 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
210000001126 granulation tissue Anatomy 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
230000036732 histological change Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
229960001388 interferon-beta Drugs 0.000 description 1
208000030776 invasive breast carcinoma Diseases 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000000938 luteal effect Effects 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
238000013178 mathematical model Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
244000005700 microbiome Species 0.000 description 1
210000004088 microvessel Anatomy 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
239000002395 mineralocorticoid Substances 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
230000014399 negative regulation of angiogenesis Effects 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
208000029522 neoplastic syndrome Diseases 0.000 description 1
238000011587 new zealand white rabbit Methods 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
210000002747 omentum Anatomy 0.000 description 1
238000001543 one-way ANOVA Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
230000007170 pathology Effects 0.000 description 1
210000003668 pericyte Anatomy 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
230000003169 placental effect Effects 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
229940048914 protamine Drugs 0.000 description 1
208000023558 pseudoxanthoma elasticum (inherited or acquired) Diseases 0.000 description 1
235000008160 pyridoxine Nutrition 0.000 description 1
239000011677 pyridoxine Substances 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000008439 repair process Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
230000004264 retinal detachment Effects 0.000 description 1
239000000790 retinal pigment Substances 0.000 description 1
150000004492 retinoid derivatives Chemical class 0.000 description 1
201000009410 rhabdomyosarcoma Diseases 0.000 description 1
JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
229960001225 rifampicin Drugs 0.000 description 1
150000003902 salicylic acid esters Chemical class 0.000 description 1
230000037390 scarring Effects 0.000 description 1
230000036280 sedation Effects 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
201000006476 shipyard eye Diseases 0.000 description 1
210000004927 skin cell Anatomy 0.000 description 1
241000894007 species Species 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
229950000213 supidimide Drugs 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
231100000211 teratogenicity Toxicity 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
230000005740 tumor formation Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
OMOMUFTZPTXCHP-UHFFFAOYSA-N valpromide Chemical compound CCCC(C(N)=O)CCC OMOMUFTZPTXCHP-UHFFFAOYSA-N 0.000 description 1
229960001930 valpromide Drugs 0.000 description 1
210000003556 vascular endothelial cell Anatomy 0.000 description 1
230000004862 vasculogenesis Effects 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
229940011671 vitamin b6 Drugs 0.000 description 1
210000004127 vitreous body Anatomy 0.000 description 1
239000002699 waste material Substances 0.000 description 1
239000008215 water for injection Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Oncology (AREA)
Immunology (AREA)
Diabetes (AREA)
Ophthalmology & Optometry (AREA)
Communicable Diseases (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Virology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Tropical Medicine & Parasitology (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

JP6520046A 1993-03-01 1994-02-24 管脈形成を抑制する方法および組成物 Withdrawn JPH08507767A (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US2504693A	1993-03-01	1993-03-01
US08/025,046		1993-03-01
US08/168,817 US5629327A (en)	1993-03-01	1993-12-15	Methods and compositions for inhibition of angiogenesis
US08/168,817		1993-12-15
PCT/US1994/001971 WO1994020085A1 (fr)	1993-03-01	1994-02-24	Procedes et compositions pour inhiber l'angiogenese

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2001050214A Division JP4065373B2 (ja)	1993-03-01	2001-02-26	サリドマイドを有効成分とする医薬品製剤

Publications (1)

Publication Number	Publication Date
JPH08507767A true JPH08507767A (ja)	1996-08-20

Family

ID=26699202

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
JP6520046A Withdrawn JPH08507767A (ja)	1993-03-01	1994-02-24	管脈形成を抑制する方法および組成物
JP2001050214A Expired - Lifetime JP4065373B2 (ja)	1993-03-01	2001-02-26	サリドマイドを有効成分とする医薬品製剤
JP2004220584A Pending JP2004359693A (ja)	1993-03-01	2004-07-28	サリドマイドを有効成分とする医薬品製剤
JP2007289175A Pending JP2008088182A (ja)	1993-03-01	2007-11-07	サリドマイドを有効成分とする医薬品製剤

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
JP2001050214A Expired - Lifetime JP4065373B2 (ja)	1993-03-01	2001-02-26	サリドマイドを有効成分とする医薬品製剤
JP2004220584A Pending JP2004359693A (ja)	1993-03-01	2004-07-28	サリドマイドを有効成分とする医薬品製剤
JP2007289175A Pending JP2008088182A (ja)	1993-03-01	2007-11-07	サリドマイドを有効成分とする医薬品製剤

Country Status (19)

Country	Link
US (18)	US5629327A (fr)
EP (4)	EP1537870A3 (fr)
JP (4)	JPH08507767A (fr)
KR (1)	KR100506043B1 (fr)
AT (2)	ATE304356T1 (fr)
AU (1)	AU676722B2 (fr)
BR (1)	BR9400764A (fr)
CA (3)	CA2157288C (fr)
CO (1)	CO4230017A1 (fr)
DE (3)	DE69434490T2 (fr)
DK (2)	DK0688211T3 (fr)
ES (2)	ES2174873T3 (fr)
FR (1)	FR08C0036I2 (fr)
LU (1)	LU91471I2 (fr)
NL (1)	NL300358I2 (fr)
NZ (4)	NZ262676A (fr)
PE (1)	PE10095A1 (fr)
PT (1)	PT688211E (fr)
WO (1)	WO1994020085A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002506861A (ja) *	1998-03-16	2002-03-05	コルジーンコーポレイション	２−（２，６−ジオキソピペリジン−３−イル）イソインドリン誘導体、その製剤および炎症性サイトカイン阻害剤としてのその使用
JP2002514578A (ja) *	1998-05-11	2002-05-21	エントレメッドインコーポレイテッド	２−フタルイミジノグルタル酸の類似体および血管新生の阻害剤としてのそれらの使用
JP2004538322A (ja) *	2001-08-06	2004-12-24	ザチルドレンズメディカルセンターコーポレイション	窒素置換サリドマイド誘導体の合成及び抗腫瘍活性
JP2009509945A (ja) *	2005-09-27	2009-03-12	天津和美生物技▲術▼有限公司	細胞の腫瘍壊死因子の放出を抑制できる５Ｈ−チエノ［３，４−ｃ］ピロール−４，６ジオン誘導物
JP2009538318A (ja) *	2006-05-26	2009-11-05	セルジーン・コーポレーション	併用療法において免疫調節化合物を用いる方法及び組成物

Families Citing this family (306)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6582959B2 (en)	1991-03-29	2003-06-24	Genentech, Inc.	Antibodies to vascular endothelial cell growth factor
US6114355A (en) *	1993-03-01	2000-09-05	D'amato; Robert	Methods and compositions for inhibition of angiogenesis
US5629327A (en)	1993-03-01	1997-05-13	Childrens Hospital Medical Center Corp.	Methods and compositions for inhibition of angiogenesis
US8143283B1 (en) *	1993-03-01	2012-03-27	The Children's Medical Center Corporation	Methods for treating blood-born tumors with thalidomide
US6228879B1 (en)	1997-10-16	2001-05-08	The Children's Medical Center	Methods and compositions for inhibition of angiogenesis
US6805865B1 (en)	1993-05-27	2004-10-19	Entremed, Inc.	Compositions and methods for treating cancer and hyperproliferative disorders
US20040248799A1 (en) *	1993-05-27	2004-12-09	Holaday John W.	Compositions and methods for treating cancer and hyperproliferative disorders
DE4422237A1 (de) *	1994-06-24	1996-01-04	Gruenenthal Gmbh	Verwendung von Lactamverbindungen als pharmazeutische Wirkstoffe
US6429221B1 (en) *	1994-12-30	2002-08-06	Celgene Corporation	Substituted imides
US6440729B1 (en) *	1995-06-30	2002-08-27	University Of Kansas Medical Center	Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
US6358735B1 (en)	1995-06-30	2002-03-19	University Of Kansas Medical Center	Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
US6518281B2 (en) *	1995-08-29	2003-02-11	Celgene Corporation	Immunotherapeutic agents
US6346510B1 (en)	1995-10-23	2002-02-12	The Children's Medical Center Corporation	Therapeutic antiangiogenic endostatin compositions
JP3263598B2 (ja) *	1995-11-01	2002-03-04	有限会社ドット	経鼻吸収用生理活性ペプチド組成物
US5798368A (en) *	1996-08-22	1998-08-25	Celgene Corporation	Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
HU228769B1 (en) *	1996-07-24	2013-05-28	Celgene Corp	Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
DK2070920T3 (da) *	1996-07-24	2011-06-14	Celgene Corp	Substituerede 2-(2,6-dioxopiperidin-3-yl)phthalimider og 1-oxoisoindoliner og fremgangsmåde til at reducere TNF-a-niveauer
DE122007000079I2 (de) *	1996-07-24	2010-08-12	Celgene Corp	Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels
US6281230B1 (en)	1996-07-24	2001-08-28	Celgene Corporation	Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en)	1996-07-24	1999-06-29	Celgene Corp	Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US5955496A (en) *	1996-08-13	1999-09-21	The Regents Of The University Of California	Dihydroxy-oxy-eicosadienoates
ATE493983T1 (de) *	1996-11-05	2011-01-15	Childrens Medical Center	Thalidomide und dexamethason für die behandlung von tumors
US6670337B1 (en)	1998-01-29	2003-12-30	Yeda Reaearch And Development Co., Ltd.	Facilitation of wound healing with CM101/GBS toxin
US5858991A (en)	1997-01-29	1999-01-12	Vanderbilt University	Facilitation of wound healing with CM101/GBS toxin
US5981508A (en) *	1997-01-29	1999-11-09	Vanderbilt University	Facilitation of repair of neural injury with CM101/GBS toxin
US6028060A (en)	1997-01-29	2000-02-22	Vanderbilt University	Treatment of chronic inflammatory diseases with CM101/GBS toxin
US6593291B1 (en)	1997-02-06	2003-07-15	Entremed, Inc.	Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
US5994388A (en) *	1997-03-18	1999-11-30	The Children's Medical Center Corporation	Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis
AU6578298A (en)	1997-03-21	1998-10-20	President And Fellows Of Harvard College	Antisense inhibition of angiogenin expression
US6174695B1 (en)	1997-08-12	2001-01-16	The Regents Of The University Of California	Epoxide hydrolase inhibitor methods
WO1999009982A1 (fr)	1997-08-25	1999-03-04	Harold Brem	Inhibiteurs d'angiogenese utilises pour prevenir des adherences et la formation de cicatrices excessives
CZ299808B6 (cs) *	1997-11-18	2008-12-03	Celgene Corporation	Substituované 2-(2,6-dioxo-3-fluoropiperidin-3-yl)izoindoliny a jejich použití za úcelem snížení hladin TNFalfa
US5955476A (en) *	1997-11-18	1999-09-21	Celgene Corporation	Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
AU3980499A (en)	1998-05-11	1999-11-29	Endowment for Research in Human Biology, Inc., The	Use of neomycin for treating angiogenesis-related diseases
US6673828B1 (en) *	1998-05-11	2004-01-06	Children's Medical Center Corporation	Analogs of 2-Phthalimidinoglutaric acid
US8197430B1 (en)	1998-05-22	2012-06-12	Biopheresis Technologies, Inc.	Method and system to remove cytokine inhibitor in patients
US6620382B1 (en) *	1998-05-22	2003-09-16	Biopheresis Technologies, Llc.	Method and compositions for treatment of cancers
US8609614B2 (en)	1998-07-22	2013-12-17	Vanderbilt University	GBS toxin receptor compositions and methods of use
US6576613B1 (en) *	1998-07-24	2003-06-10	Corvas International, Inc.	Title inhibitors of urokinase
US6703050B1 (en) *	1998-09-04	2004-03-09	The Regents Of The University Of Michigan	Methods and compositions for the prevention or treatment of cancer
US6537554B1 (en)	1998-09-10	2003-03-25	Curagen Corporation	Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
US6231889B1 (en)	1998-09-21	2001-05-15	Chronorx, Llc	Unit dosage forms for the treatment of herpes simplex
AU5991699A (en)	1998-09-21	2000-04-10	Biochem Pharma Inc.	Quinolizinones as integrin inhibitors
US6596690B2 (en) *	1998-10-06	2003-07-22	The United States Of America As Represented By The Department Of Health And Human Services	Vasostatin as marrow protectant
FR2784580B1 (fr) *	1998-10-16	2004-06-25	Biosepra Inc	Microspheres de polyvinyl-alcool et procedes de fabrication de celles-ci
US20030013739A1 (en) *	1998-12-23	2003-01-16	Pharmacia Corporation	Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
US7238711B1 (en) *	1999-03-17	2007-07-03	Cambridge University Technical Services Ltd.	Compounds and methods to inhibit or augment an inflammatory response
AU2612100A (en) *	1999-01-13	2000-08-01	Rockefeller University, The	Methods of promoting or enhancing interleukin-12 production through administration of thalidomide
CN1342146A (zh)	1999-03-18	2002-03-27	塞尔基因公司	取代的1－氧代－和1,3－二氧代异吲哚啉及其在用于减少炎性细胞因子含量的药物组合物中的用途
ES2194640T3 (es)	1999-03-31	2003-12-01	Gruenenthal Chemie	Solucion acuosa estable del derivado de la talidomida (em 12), para su administracion parenteral, y su procedimiento de preparacion.
US7629360B2 (en) *	1999-05-07	2009-12-08	Celgene Corporation	Methods for the treatment of cachexia and graft v. host disease
US6468990B1 (en) *	1999-05-17	2002-10-22	Queen's University At Kingston	Method of inhibiting binding of nerve growth factor to p75 NTR receptor
US6673843B2 (en) *	1999-06-30	2004-01-06	Emory University	Curcumin and curcuminoid inhibition of angiogenesis
US6916843B1 (en) *	1999-08-11	2005-07-12	The United States Of America As Represented By The Department Of Health And Human Services	Anti-inflammatory actions of cytochrome P450 expoxygenase-derived eicosanoids
US7087592B1 (en)	1999-08-23	2006-08-08	Entre Med, Inc.	Compositions comprising purified 2-methoxyestradiol and methods of producing same
US20040214783A1 (en)	2002-05-08	2004-10-28	Terman David S.	Compositions and methods for treatment of neoplastic disease
EP1227843B1 (fr)	1999-11-10	2009-10-14	BioPheresis Technologies, Inc.	Methode et systeme permettant de supprimer l'inhibiteur de cytokines chez des patients
US6204270B1 (en) *	1999-11-12	2001-03-20	Eyal S. Ron	Ophthalmic and mucosal preparations
IL149340A0 (en)	1999-11-18	2002-11-10	Corvas Int Inc	Nucleic acids encoding endotheliases, endotheliases and uses thereof
US6379708B1 (en) *	1999-11-20	2002-04-30	Cytologic, Llc	Method for enhancing immune responses in mammals
WO2001041755A2 (fr) *	1999-12-02	2001-06-14	The Regents Of The University Of Michigan	Compositions et methodes pour le traitement local de maladies inflammatoires
US7182953B2 (en)	1999-12-15	2007-02-27	Celgene Corporation	Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6699899B1 (en) *	1999-12-21	2004-03-02	Celgene Corporation	Substituted acylhydroxamic acids and method of reducing TNFα levels
US7700341B2 (en)	2000-02-03	2010-04-20	Dendreon Corporation	Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
CN1121218C (zh) *	2000-03-08	2003-09-17	台湾东洋药品工业股份有限公司	酞胺哌啶酮在治疗肝细胞癌的药物组合物中的应用
US20030212022A1 (en) *	2001-03-23	2003-11-13	Jean-Marie Vogel	Compositions and methods for gene therapy
DE01918975T1 (de) *	2000-03-24	2006-04-13	Biosphere Medical, Inc., Rockland	Mikrokügelchen zur aktiven Embolisierung
KR20030003708A (ko) *	2000-03-31	2003-01-10	셀진 코포레이션	시클로옥시게나제-2 활성의 저해
AU2001261474B2 (en)	2000-05-15	2006-03-09	Celgene Corporation	Compositions and methods for the treatment of cancer
EP1286671B1 (fr) *	2000-05-15	2006-04-05	Celgene Corporation	Compositions et methodes de traitement du cancer colorectal
US20030104573A1 (en) *	2000-09-11	2003-06-05	Shimkets Richard A.	Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
US6458810B1 (en)	2000-11-14	2002-10-01	George Muller	Pharmaceutically active isoindoline derivatives
ATE374609T1 (de) *	2000-11-30	2007-10-15	Childrens Medical Center	Synthese von 4-aminothalidomid enantiomeren
US20040121945A1 (en) *	2000-12-15	2004-06-24	Hong Liang	Compositions and methods for inhibiting endothelial cell proliferation
EP1226824A1 (fr) *	2001-01-24	2002-07-31	TTY Biopharm Company Limited	Utilisation de la thalidomide pour traiter le carcinome hépatocellulaire
US6632835B2 (en)	2001-02-22	2003-10-14	Nanodesign Inc.	Dibenzo[c]chromen-6-one derivatives as anti-cancer agents
US7320991B2 (en) *	2001-02-27	2008-01-22	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health	Analogs of thalidomide as potential angiogenesis inhibitors
CN1518447A (zh) *	2001-04-23	2004-08-04	��Ǵ�ѧר��	作为抗血管生成剂的新的苯邻二甲酰亚胺模拟物的合成和评估
CA2451942A1 (fr) *	2001-07-27	2003-02-13	Munirathinam Sundaramoorthy	Structure cristallisee de l'hexamere du domaine nc1 du collagene de type iv
GB0125659D0 (en) *	2001-10-25	2001-12-19	Ssl Int Plc	Spermicides
AU2002357004A1 (en) *	2001-11-20	2003-06-10	Dendreon San Diego Llc	Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
US20030139469A1 (en) *	2002-01-23	2003-07-24	The Regents Of The University Of California	Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation
EP1572078A4 (fr) *	2002-03-08	2006-08-09	Univ Emory	NOUVELLES CONSTRUCTIONS DE FACTEURS VIIa DE CURCUMINOIDES UTILISEES EN TANT QUE SUPPRESSEURS DE LA CROISSANCE TUMORALE ET DE L'ANGIOGENESE
ES2431040T3 (es) *	2002-03-08	2013-11-22	Shanghai Institutes For Biological Sciences, Cas	Detección y modulación de la angiogénesis mediada por Slit y Roundabout (Robo), y sus usos
CA2481306A1 (fr) *	2002-04-09	2003-10-23	Greenville Hospital System	Activite de modulation de metastase d'oligosaccharides hautement sulfates
US7323479B2 (en) *	2002-05-17	2008-01-29	Celgene Corporation	Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
USRE48890E1 (en)	2002-05-17	2022-01-11	Celgene Corporation	Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US7968569B2 (en)	2002-05-17	2011-06-28	Celgene Corporation	Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
CA2752124A1 (fr)	2002-05-17	2003-11-27	Celgene Corporation	Methodes et compositions a base de 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione pour le traitement et la gestion du cancer de la tete et du cou
EP2258363A1 (fr)	2002-05-17	2010-12-08	Celgene Corporation	Compositions pour le traitement des cancers
US20100129363A1 (en) *	2002-05-17	2010-05-27	Zeldis Jerome B	Methods and compositions using pde4 inhibitors for the treatment and management of cancers
US7393862B2 (en)	2002-05-17	2008-07-01	Celgene Corporation	Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US20040001801A1 (en) *	2002-05-23	2004-01-01	Corvas International, Inc.	Conjugates activated by cell surface proteases and therapeutic uses thereof
WO2004002418A2 (fr) *	2002-06-26	2004-01-08	Entremed, Inc	Compositions et procedes comprenant des antagonistes des recepteurs actives de proteines
KR20120068769A (ko)	2002-07-15	2012-06-27	더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템	음이온성 인지질 및 아미노인지질에 결합하는 선택된 항체 및 치료하는데 있어서 이의 용도
US7642252B2 (en) *	2002-07-22	2010-01-05	Chemgenex Pharmaceuticals, Inc.	Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof
GEP20074270B (en) *	2002-07-23	2007-12-25	Univ Michigan	Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
US11116782B2 (en)	2002-10-15	2021-09-14	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
EP1900369A1 (fr)	2002-10-15	2008-03-19	Celgene Corporation	Procédé d'utilisation et compositions comprenant des composés immunomodulateurs pour le traitement et la gestion de syndromes myélodysplasiques
US7189740B2 (en) *	2002-10-15	2007-03-13	Celgene Corporation	Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
CN1713905A (zh) *	2002-10-15	2005-12-28	细胞基因公司	用于治疗骨髓增生异常综合征的选择性细胞因子抑制药
US8404717B2 (en) *	2002-10-15	2013-03-26	Celgene Corporation	Methods of treating myelodysplastic syndromes using lenalidomide
US8404716B2 (en)	2002-10-15	2013-03-26	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US20050203142A1 (en) *	2002-10-24	2005-09-15	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040087558A1 (en) *	2002-10-24	2004-05-06	Zeldis Jerome B.	Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US7776907B2 (en) *	2002-10-31	2010-08-17	Celgene Corporation	Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
NZ540186A (en) *	2002-10-31	2008-03-28	Celgene Corp	Composition for the treatment of macular degeneration
US20040091455A1 (en) *	2002-10-31	2004-05-13	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) *	2002-11-06	2009-07-21	Celgene Corporation	Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) *	2002-11-06	2011-10-11	Celgene Corporation	Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
TW200501945A (en)	2002-11-06	2005-01-16	Celgene Corp	Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
JP2006512318A (ja) *	2002-11-12	2006-04-13	アルコン，インコーポレイテッド	眼の血管新生もしくは水腫状の疾患および障害を処置するためのヒストンデアセチラーゼインヒビター
US9006267B2 (en) *	2002-11-14	2015-04-14	Celgene Corporation	Pharmaceutical compositions and dosage forms of thalidomide
US7230012B2 (en) *	2002-11-14	2007-06-12	Celgene Corporation	Pharmaceutical compositions and dosage forms of thalidomide
US8431396B2 (en)	2003-03-21	2013-04-30	The Cleveland Clinic Foundation	Anti-angiogenic peptides
US7868011B2 (en) *	2003-04-09	2011-01-11	General Atomics	Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus
US7196093B2 (en) *	2003-04-09	2007-03-27	General Atomics	Reversible inhibitors of SAH hydrolase and uses thereof
US7517887B2 (en) *	2003-04-09	2009-04-14	General Atomics	Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
DE10323898A1 (de)	2003-05-26	2004-12-23	Wilex Ag	Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe
EP1633367A2 (fr) *	2003-05-28	2006-03-15	EntreMed, Inc.	Agents anti-angiogenese
WO2005016326A2 (fr) *	2003-07-11	2005-02-24	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Analogues de la thalidomide utilises comme inhibiteurs potentiels de l'angiogenese
TWI476206B (zh)	2003-07-18	2015-03-11	Amgen Inc	對肝細胞生長因子具專一性之結合劑
UA83504C2 (en)	2003-09-04	2008-07-25	Селджин Корпорейшн	Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7973057B2 (en) *	2003-09-17	2011-07-05	The United States Of America As Represented By The Department Of Health And Human Services	Thalidomide analogs
US8952895B2 (en)	2011-06-03	2015-02-10	Apple Inc.	Motion-based device operations
US20080027113A1 (en) *	2003-09-23	2008-01-31	Zeldis Jerome B	Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration
US7612096B2 (en) *	2003-10-23	2009-11-03	Celgene Corporation	Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
US20050100529A1 (en) *	2003-11-06	2005-05-12	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
KR20060124607A (ko) *	2003-11-06	2006-12-05	셀진 코포레이션	암 및 그 밖의 질환의 치료 및 관리를 위하여탈리도마이드를 사용하는 방법 및 조성물
WO2005046686A1 (fr) *	2003-11-06	2005-05-26	Celgene Corporation	Procedes et compositions utilisant la thalidomide dans le traitement et la gestion des cancers ou d'autres maladies
KR20060109979A (ko) *	2003-12-02	2006-10-23	셀진 코포레이션	혈색소병증　및　빈혈의　치료　및　관리를　위한　방법및　조성물
US20050143344A1 (en) *	2003-12-30	2005-06-30	Zeldis Jerome B.	Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
US7430276B2 (en) *	2004-02-25	2008-09-30	Nanodynamics-88	Low dose X-ray mammography method
CA2558014A1 (fr) *	2004-03-12	2005-09-29	Entremed, Inc.	Agents anti-angiogeniques
CA2560221C (fr) *	2004-03-22	2010-12-07	Celgene Corporation	Procedes d'utilisation et compositions comprenant des composes destines au traitement et a la gestion de maladies ou de troubles de la peau
US20050222209A1 (en) *	2004-04-01	2005-10-06	Zeldis Jerome B	Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
US20080213213A1 (en) *	2004-04-14	2008-09-04	Zeldis Jerome B	Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione
AU2004319758A1 (en) *	2004-04-14	2005-11-24	Celgene Corporation	Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
BRPI0510167A (pt) *	2004-04-23	2007-10-02	Celgene Corp	método para tratar, prevenir ou controlar hipertensão pulmonar
US20050239842A1 (en) *	2004-04-23	2005-10-27	Zeldis Jerome B	Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
JP2008511340A (ja) *	2004-04-30	2008-04-17	バイオフェレシステクノロジーズ，インコーポレイテッド	患者において可溶性ｔｎｆｒ１、可溶性ｔｎｆｒ２、および可溶性ｉｌ２を除去する方法およびシステム
US7273890B1 (en) *	2004-06-08	2007-09-25	Sagittarius Life Science Corp.	ST104P, an anti-angiogenic agent
JP2008510726A (ja) *	2004-08-20	2008-04-10	エントレメッドインコーポレイテッド	プロテイナーゼ活性化受容体アンタゴニストを含む組成物および方法
EP1797068B1 (fr) *	2004-09-03	2013-10-09	Celgene Corporation	Procedes de preparation de 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines substituees
WO2006050057A2 (fr) *	2004-10-28	2006-05-11	Celgene Corporation	Methodes et compositions utilisant des modulateurs de pde4 pour le traitement et la gestion de lesions du systeme nerveux central
ZA200704890B (en) *	2004-11-23	2008-09-25	Celgene Corp	Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
KR20140090270A (ko)	2005-05-09	2014-07-16	바이오스피어 메디칼 에스.에이.	마이크로스피어 및 비이온성 조영제를 사용하는 조성물 및 방법
US20060270707A1 (en) *	2005-05-24	2006-11-30	Zeldis Jerome B	Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
US20080167272A1 (en) *	2005-06-16	2008-07-10	Auckland Uniservices Limited	Thalidomide metabolites and methods of use
MX2007016290A (es)	2005-06-30	2008-03-10	Celgene Corp	Procesos para la preparacion de compuestos de 4-amino-2(2,6-dioxopiperidin-3-il)isoindolin-1,3-diona.
WO2007009001A1 (fr) *	2005-07-12	2007-01-18	The Regents Of The University Of California	Utilisation d'acides cis-époxyéicosatriénoïques et d'inhibiteurs de l'époxyde hydrolase soluble pour atténuer des troubles de la vue
US20080138295A1 (en) *	2005-09-12	2008-06-12	Celgene Coporation	Bechet's disease using cyclopropyl-N-carboxamide
US20070065514A1 (en) *	2005-09-22	2007-03-22	Howell Mark D	Method for enhancing immune responses in mammals
AU2006301292A1 (en) *	2005-10-14	2007-04-19	F. Hoffmann-La Roche Ag	Regimen of administration for 5-(2-chlorophenyl)-1 ,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo (3, 4.-b) (1, 4) benzodiazepine
US20070155791A1 (en) *	2005-12-29	2007-07-05	Zeldis Jerome B	Methods for treating cutaneous lupus using aminoisoindoline compounds
WO2007090127A2 (fr) *	2006-01-30	2007-08-09	Surgica Corporation	Particules d'embolisation intravasculaire compressible, procedes connexes et systemes d'administration
WO2007090130A2 (fr) *	2006-01-30	2007-08-09	Surgica Corporation	Particules d'embolisation intravasculaire et procedes associes
CA2646065C (fr) *	2006-03-20	2014-01-14	Entremed, Inc.	2-methoxyestradiol presentant une activite anti-arthritique pouvant modifier l'evolution de la maladie
US20070226632A1 (en) *	2006-03-21	2007-09-27	Nokia Corporation	Method, electronic device and computer program product for enhancing contact list functionality
WO2007120669A1 (fr) *	2006-04-13	2007-10-25	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Composés tetrahalogénés utilisés comme inhibiteurs d'angiogenèse
US20080064876A1 (en) *	2006-05-16	2008-03-13	Muller George W	Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
US20080051431A1 (en) *	2006-05-26	2008-02-28	Dominique Verhelle	Methods and compositions using immunomodulatory compounds in combination therapy
WO2008007979A1 (fr) *	2006-07-12	2008-01-17	Auckland Uniservices Limited	Dérivés de l'acide benzoïque ayant des propriétés immunomodulatrices et anticancéreuses
US8217177B2 (en)	2006-07-14	2012-07-10	Amgen Inc.	Fused heterocyclic derivatives and methods of use
PE20080403A1 (es)	2006-07-14	2008-04-25	Amgen Inc	Derivados heterociclicos fusionados y metodos de uso
EP2068877A4 (fr)	2006-07-19	2011-09-21	Cleveland Clinic Foundation	Composés et méthodes de modulation de l'angiogenèse
CL2007002218A1 (es) *	2006-08-03	2008-03-14	Celgene Corp Soc Organizada Ba	Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
CN101138634A (zh) *	2006-09-07	2008-03-12	于保法	用于治疗肿瘤的组合物
US20080075690A1 (en) *	2006-09-22	2008-03-27	Mark Douglas Howell	Method for enhancing immune responses in mammals
MX2009008531A (es)	2007-02-16	2009-08-26	Amgen Inc	Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
JP5550546B2 (ja) *	2007-04-13	2014-07-16	ケムジェネックス・ファーマシューティカルズ・インコーポレイテッド	経口セファロタキシン剤形
US7893045B2 (en)	2007-08-07	2011-02-22	Celgene Corporation	Methods for treating lymphomas in certain patient populations and screening patients for said therapy
PL2188313T3 (pl)	2007-08-21	2018-04-30	Amgen, Inc.	Białka wiążące ludzki antygen c-fms
CN101970012A (zh)	2007-09-14	2011-02-09	日东电工株式会社	药物载体
AU2008304619C1 (en) *	2007-09-26	2020-06-04	Indiana University Research And Technology Corporation	Benzoquinone derivative E3330 in combination with chemotherapeutic agents for the treatment of cancer and angiogenesis
US11331294B2 (en)	2007-09-26	2022-05-17	Indiana University Research And Technology Corporation	Benzoquinone derivative E3330 in combination with chemotherapeutic agents for the treatment of bladder cancer
CA2705152C (fr)	2007-11-09	2016-10-11	Peregrine Pharmaceuticals, Inc.	Compositions d'anticorps anti-vegf et procedes correspondants
US20090137631A1 (en) *	2007-11-22	2009-05-28	National Yang-Ming University	Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression
WO2010005527A1 (fr)	2008-06-30	2010-01-14	Angioblast Systems, Inc.	Traitement de maladies oculaires et d’une néovascularisation excessive utilisant un traitement combiné
EP2323679A4 (fr)	2008-07-25	2012-08-22	Univ Colorado	Inhibiteurs de clip et procédés de modulation de la fonction immune
CN102143996A (zh) *	2008-10-30	2011-08-03	大卫·刘	微球形多孔可生物相容支架及制造该支架的方法和装置
BRPI1007855B1 (pt)	2009-05-19	2020-03-10	Celgene Corporation	Formas de dosagem oral compreendendo 4-amino-2-(2,6-dioxopiperidina-3-il)isoindolina-1,3-diona
EP2436387B1 (fr)	2009-05-25	2018-07-25	Celgene Corporation	Composition pharmaceutique contenant crbn et son utilisation dans le traitement des maladies du cortex cerebral.
GB0914330D0 (en)	2009-08-17	2009-09-30	Univ Dublin City	A method of predicting response to thalidomide in multiple myeloma patients
US20120183546A1 (en)	2009-09-23	2012-07-19	Amgen Inc.	Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane
WO2012078492A1 (fr)	2010-12-06	2012-06-14	Celgene Corporation	Traitement d'association avec du lénalidomide et un inhibiteur de cdk pour traiter le myélome multiple
EP2649095B1 (fr)	2010-12-10	2021-10-06	Aleksander S. Popel	Peptides mimétiques dérivés de collagène de type iv et leur utilisation pour traiter des maladies dépendantes de l'angiogenèse et de la lymphangiogenèse
EP2937349B1 (fr)	2011-03-23	2016-12-28	Amgen Inc.	Doubles inhibiteurs tricycliques fusionnés de cdk 4/6 et flt3
AU2012249491B2 (en)	2011-04-29	2016-12-15	Celgene Corporation	Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
WO2013003606A1 (fr)	2011-06-29	2013-01-03	Amgen Inc.	Biomarqueur prédictif de la survie dans le traitement du carcinome à cellules rénales
WO2013025939A2 (fr)	2011-08-16	2013-02-21	Indiana University Research And Technology Corporation	Composés et méthodes de traitement du cancer par l'inhibition du récepteur de l'urokinase
US20130058926A1 (en) *	2011-08-30	2013-03-07	Shiseido Company, Ltd.	Method for alleviating and/or preventing skin reddening
US8927725B2 (en)	2011-12-02	2015-01-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Thio compounds
WO2013126394A1 (fr)	2012-02-21	2013-08-29	Celgene Corporation	Formes solides de 3-(4-nitro-1-oxoisoindolin-2 - yl)pipéridine -2,6 - dione
AR090263A1 (es)	2012-03-08	2014-10-29	Hoffmann La Roche	Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
ES2872967T3 (es) *	2012-06-29	2021-11-03	Celgene Corp	Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
US9587281B2 (en)	2012-08-14	2017-03-07	Celgene Corporation	Cereblon isoforms and their use as biomarkers for therapeutic treatment
AU2013204922B2 (en)	2012-12-20	2015-05-14	Celgene Corporation	Chimeric antigen receptors
WO2014124280A1 (fr)	2013-02-08	2014-08-14	Institute For Myeloma & Bone Cancer Research	Méthodes de diagnostic, de pronostic et de surveillance améliorées pour un myélome multiple, une leucémie lymphoïde chronique et un lymphome non hodgkinien à lymphocytes b
JP2016507307A (ja)	2013-02-13	2016-03-10	カルティヒール（２００９）リミティド	細胞及び組織の付着及び血管新生の軽減又は予防のための固体基材
JP6493692B2 (ja)	2013-03-15	2019-04-10	セルジーンコーポレイション	修飾されたｔリンパ球
EP2815749A1 (fr)	2013-06-20	2014-12-24	IP Gesellschaft für Management mbH	Forme solide de 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione ayant un réseau de diffraction de rayons X spécifique
US9198898B2 (en)	2013-06-24	2015-12-01	Tigercat Pharma, Inc.	Use of NK-1 receptor antagonists in pruritus
US8906951B1 (en)	2013-06-24	2014-12-09	Tigercat Pharma, Inc.	Use of NK-1 receptor antagonists in pruritus
AU2015210999A1 (en)	2014-01-29	2016-07-21	Otsuka Pharmaceutical Co., Ltd.	Device-based risk management of a therapeutic
WO2015184087A2 (fr)	2014-05-28	2015-12-03	Institute For Myeloma & Bone Cancer Research	Effets anti-cancéreux d'inhibiteurs de jak2 en combinaison avec des dérivés de thalidomide et des glucocorticoïdes
EP3827836A1 (fr)	2014-06-27	2021-06-02	Celgene Corporation	Compositions et procédés pour induire des modifications conformationnelles dans céréblon et d'autres ubiquitine ligases e3
AU2015305449B2 (en)	2014-08-22	2021-05-06	Celgene Corporation	Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
NZ731789A (en)	2014-10-30	2019-04-26	Kangpu Biopharmaceuticals Ltd	Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
WO2016086070A1 (fr)	2014-11-26	2016-06-02	Baofa Yu	Chimio-immunothérapie haptène-améliorée par chimio-immunothérapie intratumorale personnalisée par incision ultra-minimale
WO2016209972A1 (fr)	2015-06-26	2016-12-29	Amgen Inc.	Biomarqueur de survie dans le traitement d'un carcinome à cellules rénales avec un inhibiteur de vegfr et un inhibiteur d'ang2
HUE065109T2 (hu)	2015-06-26	2024-05-28	Celgene Corp	Eljárások Kaposi-szarkóma vagy KSHV-indukált limfóma kezelésére immunomodulátor vegyületek alkalmazásával, valamint biomarkerek alkalmazása
WO2017019496A1 (fr)	2015-07-24	2017-02-02	Berenson James Richard	Modulateurs de la gamma-sécrétase pour le traitement de dysfonctionnement du système immunitaire
AU2016330967B2 (en) *	2015-09-30	2021-03-25	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Thalidomide analogs and methods of use
HUE068392T2 (hu)	2015-10-21	2024-12-28	Otsuka Pharma Co Ltd	Benzolaktám vegyületek mint fehérje kináz gátlók
WO2017117118A1 (fr)	2015-12-28	2017-07-06	Celgene Corporation	Compositions et méthodes pour induire des modifications conformationnelles dans céréblon et d'autres ubiquitine ligases e3
ES2898329T3 (es)	2016-01-12	2022-03-07	Oncotracker Inc	Métodos mejorados para supervisar el estado inmunitario de un sujeto
MX2018011648A (es)	2016-03-31	2019-01-30	Omeros Corp	Metodos para la inhibicion de fibrosis en un sujeto en necesidad del mismo.
BR112019011065A2 (pt)	2016-12-03	2019-10-01	Juno Therapeutics Inc	métodos para determinação da dosagem de células t car
CN110248678A (zh)	2016-12-03	2019-09-17	朱诺治疗学股份有限公司	调节car-t细胞的方法
CN110366550A (zh)	2016-12-22	2019-10-22	美国安进公司	作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物
EP3576726A1 (fr)	2017-02-06	2019-12-11	Massachusetts Institute Of Technology	Méthodes et produits associés à des inhibiteurs de glutaminase
GB201706327D0 (en)	2017-04-20	2017-06-07	Otsuka Pharma Co Ltd	A pharmaceutical compound
CN118948892A (zh)	2017-05-01	2024-11-15	朱诺治疗学股份有限公司	细胞疗法与免疫调节化合物的组合
AU2018273356B2 (en)	2017-05-22	2021-09-16	Amgen Inc.	KRAS G12C inhibitors and methods of using the same
US10093647B1 (en)	2017-05-26	2018-10-09	Celgene Corporation	Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
AU2018275894B2 (en)	2017-06-02	2025-04-24	Juno Therapeutics, Inc.	Articles of manufacture and methods for treatment using adoptive cell therapy
US11635435B2 (en)	2017-06-13	2023-04-25	Oncotracker, Inc.	Diagnostic, prognostic, and monitoring methods for solid tumor cancers
JP2020526194A (ja)	2017-06-29	2020-08-31	ジュノーセラピューティクスインコーポレイテッド	免疫療法薬と関連する毒性を評価するためのマウスモデル
US10513515B2 (en)	2017-08-25	2019-12-24	Biotheryx, Inc.	Ether compounds and uses thereof
AU2018329920B2 (en)	2017-09-08	2022-12-01	Amgen Inc.	Inhibitors of KRAS G12C and methods of using the same
US10093649B1 (en)	2017-09-22	2018-10-09	Celgene Corporation	Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
US10093648B1 (en)	2017-09-22	2018-10-09	Celgene Corporation	Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
WO2019089858A2 (fr)	2017-11-01	2019-05-09	Juno Therapeutics, Inc.	Procédés d'évaluation ou de surveillance d'une réponse à une thérapie cellulaire
SG11202003501XA (en)	2017-11-01	2020-05-28	Juno Therapeutics Inc	Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
MA51210A (fr)	2017-12-01	2020-10-07	Juno Therapeutics Inc	Procédés de dosage et de modulation de cellules génétiquement modifiées
MA51184A (fr)	2017-12-15	2020-10-21	Juno Therapeutics Inc	Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés
US10537585B2 (en)	2017-12-18	2020-01-21	Dexcel Pharma Technologies Ltd.	Compositions comprising dexamethasone
WO2019210080A1 (fr) *	2018-04-25	2019-10-31	The Regents Of The University Of California	Méthodes et compositions pour troubles du squelette et neurologiques
CA3098574A1 (fr)	2018-05-04	2019-11-07	Amgen Inc.	Inhibiteurs de kras g12c et leurs procedes d'utilisation
EP3788053B1 (fr)	2018-05-04	2024-07-10	Amgen Inc.	Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA52564A (fr)	2018-05-10	2021-03-17	Amgen Inc	Inhibiteurs de kras g12c pour le traitement du cancer
US11096939B2 (en)	2018-06-01	2021-08-24	Amgen Inc.	KRAS G12C inhibitors and methods of using the same
MX2020012204A (es)	2018-06-11	2021-03-31	Amgen Inc	Inhibidores de kras g12c para tratar el cáncer.
US11285156B2 (en)	2018-06-12	2022-03-29	Amgen Inc.	Substituted piperazines as KRAS G12C inhibitors
CA3106239A1 (fr)	2018-07-27	2020-01-30	Biotheryx, Inc.	Composes bifonctionnels agissant par agonisme sur des cdk
CA3117978A1 (fr)	2018-11-08	2020-05-14	Juno Therapeutics, Inc.	Procedes et combinaisons pour le traitement et la modulation de lymphocytes t
JP7516029B2 (ja)	2018-11-16	2024-07-16	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
IL283218B2 (en)	2018-11-16	2025-11-01	Juno Therapeutics Inc	Dosing methods of engineered T cells for the treatment of malignant B cells
JP7377679B2 (ja)	2018-11-19	2023-11-10	アムジエン・インコーポレーテツド	がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
AU2019384118B2 (en)	2018-11-19	2025-06-12	Amgen Inc.	KRAS G12C inhibitors and methods of using the same
PT3886875T (pt)	2018-11-30	2024-06-27	Juno Therapeutics Inc	Métodos para tratamento utilizando terapia celular adotiva
JP2022513967A (ja)	2018-12-20	2022-02-09	アムジエン・インコーポレーテツド	Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
JP7686559B2 (ja)	2018-12-20	2025-06-02	アムジエン・インコーポレーテツド	Ｋｉｆ１８ａ阻害剤
MA54543A (fr)	2018-12-20	2022-03-30	Amgen Inc	Inhibiteurs de kif18a
AU2019401495B2 (en)	2018-12-20	2025-06-26	Amgen Inc.	Heteroaryl amides useful as KIF18A inhibitors
SG11202107976SA (en)	2019-01-29	2021-08-30	Juno Therapeutics Inc	Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
MX2021010323A (es)	2019-03-01	2021-12-10	Revolution Medicines Inc	Compuestos bicíclicos de heterociclilo y usos de este.
MX2021010319A (es)	2019-03-01	2021-12-10	Revolution Medicines Inc	Compuestos biciclicos de heteroarilo y usos de estos.
EP3738593A1 (fr)	2019-05-14	2020-11-18	Amgen, Inc	Dosage d'inhibiteur de kras pour le traitement de cancers
WO2020236947A1 (fr)	2019-05-21	2020-11-26	Amgen Inc.	Formes à l'état solide
EP4007752B1 (fr)	2019-08-02	2025-09-24	Amgen Inc.	Inhibiteurs de kif18a
EP4007756B1 (fr)	2019-08-02	2025-12-24	Amgen Inc.	Inhibiteurs de kif18a
EP4007638A1 (fr)	2019-08-02	2022-06-08	Amgen Inc.	Dérivés de pyridine en tant qu'inhibiteurs de kif18a
EP4048671B1 (fr)	2019-10-24	2026-03-18	Amgen Inc.	Dérivés de pyridopyrimidine utiles en tant qu'inhibiteurs de kras g12c et de kras g12d dans le traitement du cancer
AU2020377925A1 (en)	2019-11-04	2022-05-05	Revolution Medicines, Inc.	Ras inhibitors
IL322454A (en)	2019-11-04	2025-09-01	Revolution Medicines Inc	ras inhibitors
CA3156359A1 (fr)	2019-11-08	2021-05-14	Adrian Liam Gill	Composes heteroaryles bicycliques et leurs utilisations
JP7837865B2 (ja)	2019-11-14	2026-03-31	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤化合物の改良合成法
JP2023501528A (ja)	2019-11-14	2023-01-18	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤化合物の改善された合成
EP4065231A1 (fr)	2019-11-27	2022-10-05	Revolution Medicines, Inc.	Inhibiteurs de ras covalents et leurs utilisations
WO2021142026A1 (fr)	2020-01-07	2021-07-15	Revolution Medicines, Inc.	Dosage d'inhibiteurs de shp2 et méthodes de traitement du cancer
WO2021222150A2 (fr)	2020-04-28	2021-11-04	Anwita Biosciences, Inc.	Polypeptides d'interleukine-2 et protéines de fusion de ceux-ci, ainsi que leurs compositions pharmaceutiques et leurs applications thérapeutiques
IL299131A (en)	2020-06-18	2023-02-01	Revolution Medicines Inc	Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
US20250195521A1 (en)	2020-09-03	2025-06-19	Revolution Medicines, Inc.	Use of sos1 inhibitors to treat malignancies with shp2 mutations
CA3194067A1 (fr)	2020-09-15	2022-03-24	Revolution Medicines, Inc.	Derives d'indole servant d'inhibiteurs dans le traitement du cancer
JP7849366B2 (ja)	2020-12-22	2026-04-21	キル・レガー・セラピューティクス・インコーポレーテッド	Ｓｏｓ１阻害剤およびその使用
KR20240017811A (ko)	2021-05-05	2024-02-08	레볼루션 메디슨즈, 인크.	암의 치료를 위한 ras 억제제
JP2024516450A (ja)	2021-05-05	2024-04-15	レボリューションメディシンズインコーポレイテッド	共有結合性ｒａｓ阻害剤及びその使用
TW202309052A (zh)	2021-05-05	2023-03-01	美商銳新醫藥公司	Ｒａｓ抑制劑
AR127308A1 (es)	2021-10-08	2024-01-10	Revolution Medicines Inc	Inhibidores ras
EP4227307A1 (fr)	2022-02-11	2023-08-16	Genzyme Corporation	Composés pyrazolopyrazine en tant qu'inhibiteurs de shp2
KR20240156373A (ko)	2022-03-07	2024-10-29	암젠 인크	4-메틸-2-프로판-2-일-피리딘-3-카르보니트릴의 제조 방법
JP2025510572A (ja)	2022-03-08	2025-04-15	レボリューションメディシンズインコーポレイテッド	免疫不応性肺癌を治療するための方法
WO2023240263A1 (fr)	2022-06-10	2023-12-14	Revolution Medicines, Inc.	Inhibiteurs de ras macrocycliques
EP4543923A1 (fr)	2022-06-22	2025-04-30	Juno Therapeutics, Inc.	Méthodes de traitement pour thérapie de deuxième ligne par cellules car-t ciblées par cd19
AU2023358792A1 (en)	2022-10-14	2025-04-17	Black Diamond Therapeutics, Inc.	Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
WO2024097905A1 (fr)	2022-11-02	2024-05-10	Celgene Corporation	Méthodes de traitement au moyen d'une thérapie par lymphocytes t et d'une thérapie d'entretien par agent immunomodulateur
AU2024241633A1 (en)	2023-03-30	2025-11-06	Revolution Medicines, Inc.	Compositions for inducing ras gtp hydrolysis and uses thereof
CR20250420A (es)	2023-04-07	2025-11-20	Revolution Medicines Inc	Inhibidores macrocíclicos de ras
CN121100123A (zh)	2023-04-14	2025-12-09	锐新医药公司	Ras抑制剂的结晶形式
TW202508595A (zh)	2023-05-04	2025-03-01	美商銳新醫藥公司	用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en)	2023-08-07	2025-02-13	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
WO2025076472A1 (fr)	2023-10-06	2025-04-10	Juno Therapeutics, Inc.	Polythérapies comprenant une thérapie cellulaire exprimant un car ciblant gprc5d, méthodes et utilisations associés
AU2024360465A1 (en)	2023-10-12	2026-04-09	Revolution Medicines, Inc.	Macrocyclic ras inhibitors
TW202542151A (zh)	2023-12-22	2025-11-01	美商銳格醫藥有限公司	Ｓｏｓ１抑制劑及其用途
TW202547461A (zh)	2024-05-17	2025-12-16	美商銳新醫藥公司	Ｒａｓ抑制劑
WO2025255438A1 (fr)	2024-06-07	2025-12-11	Revolution Medicines, Inc.	Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras
WO2025265060A1 (fr)	2024-06-21	2025-12-26	Revolution Medicines, Inc.	Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr)	2024-06-28	2026-01-02	Revolution Medicines, Inc.	Inhibiteurs de ras
WO2026015825A1 (fr)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026015796A1 (fr)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015801A1 (fr)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026015790A1 (fr)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026050446A1 (fr)	2024-08-29	2026-03-05	Revolution Medicines, Inc.	Inhibiteurs de ras
WO2026072904A2 (fr)	2024-09-26	2026-04-02	Revolution Medicines, Inc.	Compositions et méthodes de traitement du cancer du poumon

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB768821A (en)	1954-05-17	1957-02-20	Gruenenthal Chemie	Novel products of the amino-piperidine-2, 6-dione series
US2830991A (en) *	1954-05-17	1958-04-15	Gruenenthal Chemie	Products of the amino-piperidine-2-6-dione series
US3142672A (en) *	1957-09-03	1964-07-28	Takeda Pharmaceutical	Derivatives of nu-alpha-phenyl-and nu-alpha-biphenylylbutyric acids and amino sugars
US3560495A (en) *	1965-05-08	1971-02-02	Ernst Frankus	1-heterocyclic amino methyl or 1-heterocyclic hydrazino methyl-3-phthalimido or (3',6'-dithia-3',4',5',6'-tetrahydrophthalimido)-pyrrolidinediones-2,5 or piperidinediones-2,6
US3563986A (en) *	1965-10-12	1971-02-16	Ernst Frankus	4 - phthalimido - n - heterocyclic amino methyl or piperidino hydrazino piperidine diones 2,6
DE1670551B2 (de) *	1965-10-30	1973-01-25		Salze trisubstituierter s-triazine
AT278739B (de) *	1966-11-08	1970-02-10	Kwizda Fa F Johann	Verfahren zur Herstellung von neuen Anhydriden und Imiden substituierter Dicarbonsäuren
US3705162A (en) *	1967-07-01	1972-12-05	Gruenenthal Chemie	4-phthalimidine glutarimides
US4552888A (en) *	1982-01-15	1985-11-12	Eli Lilly And Company	Ascorbic acid ethers in angiogene
FI830078L (fi) *	1982-01-15	1983-07-16	Lilly Co Eli	Askorbinsyraetrar och liknande foereningar
US5001116A (en) *	1982-12-20	1991-03-19	The Children's Medical Center Corporation	Inhibition of angiogenesis
US4994443A (en) *	1982-12-20	1991-02-19	The Children's Medical Center Corporation	Inhibition of angiogenesis
JP2544136B2 (ja) *	1986-05-23	1996-10-16	第一製薬株式会社	硫酸化多糖体ｄｓ４１５２を含有する血管新生抑制剤及び抗腫瘍剤
US4808402A (en) *	1987-05-29	1989-02-28	Northwestern University	Method and compositions for modulating neovascularization
ES2059571T3 (es) *	1988-01-19	1994-11-16	Takeda Chemical Industries Ltd	Fumagilina como agente angiostatico.
AT393221B (de) *	1988-02-03	1991-09-10	Leopold Pharma Gmbh	Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken
US5021404A (en) *	1988-04-20	1991-06-04	The Children's Medical Center Corporation	Angiostatic collagen modulators
CA1329771C (fr) *	1988-09-01	1994-05-24	Shoji Kishimoto	Agent inhibiteur de l'angiogenese
US5049154A (en) *	1989-08-07	1991-09-17	Berkshire Research & Development, Inc.	Adjustable intra-luminal valvulotome
JPH03109324A (ja) *	1989-09-22	1991-05-09	Microbial Chem Res Found	血管新生阻害剤
GB9000644D0 (en) *	1990-01-11	1990-03-14	Erba Carlo Spa	New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds
US5192744A (en)	1990-01-12	1993-03-09	Northwestern University	Method of inhibiting angiogenesis of tumors
KR0166088B1 (ko) *	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5405851A (en) *	1990-06-19	1995-04-11	Burroughs Wellcome Co.	Pharmaceutical compounds
US5399363A (en)	1991-01-25	1995-03-21	Eastman Kodak Company	Surface modified anticancer nanoparticles
AU1531492A (en) *	1991-02-14	1992-09-15	Rockefeller University, The	Method for controlling abnormal concentration tnf alpha in human tissues
CA2104776C (fr) *	1991-04-17	2003-12-09	Kurt Eger	Derives de la thalidomide, methode pour leur fabrication et leur utilisation dans des medicaments
US5679696A (en)	1992-07-28	1997-10-21	Rhone-Poulenc Rorer Limited	Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group
US5629327A (en) *	1993-03-01	1997-05-13	Childrens Hospital Medical Center Corp.	Methods and compositions for inhibition of angiogenesis
US6114355A (en) *	1993-03-01	2000-09-05	D'amato; Robert	Methods and compositions for inhibition of angiogenesis
US6228879B1 (en) *	1997-10-16	2001-05-08	The Children's Medical Center	Methods and compositions for inhibition of angiogenesis
DE4320157A1 (de)	1993-06-18	1994-12-22	Bayer Ag	Verwendung von 1,2,4-Dithiazolium-Salzen als Chemotherapeutica
US5605914A (en)	1993-07-02	1997-02-25	Celgene Corporation	Imides
WO1995004533A2 (fr)	1993-08-04	1995-02-16	Andrulis Pharmaceuticals Corporation	Traitement de la polyarthrite rhumatoide par le thalidomide seul ou associe a d'autres anti-inflammatoires
US5405855A (en)	1993-12-23	1995-04-11	Andrulis Pharmaceuticals Corp.	Treatment of insulin resistant diabetes with thalidomine
US5434170A (en)	1993-12-23	1995-07-18	Andrulis Pharmaceuticals Corp.	Method for treating neurocognitive disorders
US5443824A (en)	1994-03-14	1995-08-22	Piacquadio; Daniel J.	Topical thalidomide compositions for surface or mucosal wounds, ulcerations, and lesions
WO1996029092A1 (fr) *	1995-03-17	1996-09-26	Toray Industries, Inc.	Inhibiteur de vascularisation de la cornee
US5731325A (en)	1995-06-06	1998-03-24	Andrulis Pharmaceuticals Corp.	Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
US5643915A (en)	1995-06-06	1997-07-01	Andrulis Pharmaceuticals Corp.	Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
US5654312A (en)	1995-06-07	1997-08-05	Andrulis Pharmaceuticals	Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents
US6281230B1 (en) *	1996-07-24	2001-08-28	Celgene Corporation	Isoindolines, method of use, and pharmaceutical compositions
US5798368A (en) *	1996-08-22	1998-08-25	Celgene Corporation	Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
US5635517B1 (en) *	1996-07-24	1999-06-29	Celgene Corp	Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
CN1342146A (zh)	1999-03-18	2002-03-27	塞尔基因公司	取代的1－氧代－和1,3－二氧代异吲哚啉及其在用于减少炎性细胞因子含量的药物组合物中的用途

1993
- 1993-12-15 US US08/168,817 patent/US5629327A/en not_active Expired - Lifetime
1994
- 1994-02-24 ES ES94909773T patent/ES2174873T3/es not_active Expired - Lifetime
- 1994-02-24 DK DK94909773T patent/DK0688211T3/da active
- 1994-02-24 DK DK02011928T patent/DK1264597T3/da active
- 1994-02-24 AU AU62486/94A patent/AU676722B2/en not_active Expired
- 1994-02-24 DE DE69434490T patent/DE69434490T2/de not_active Expired - Lifetime
- 1994-02-24 NZ NZ262676A patent/NZ262676A/xx not_active IP Right Cessation
- 1994-02-24 JP JP6520046A patent/JPH08507767A/ja not_active Withdrawn
- 1994-02-24 EP EP05002523A patent/EP1537870A3/fr not_active Withdrawn
- 1994-02-24 DE DE69430796T patent/DE69430796T2/de not_active Expired - Lifetime
- 1994-02-24 WO PCT/US1994/001971 patent/WO1994020085A1/fr not_active Ceased
- 1994-02-24 NZ NZ535671A patent/NZ535671A/en not_active IP Right Cessation
- 1994-02-24 ES ES02011928T patent/ES2245711T3/es not_active Expired - Lifetime
- 1994-02-24 EP EP02012280A patent/EP1245229A3/fr not_active Withdrawn
- 1994-02-24 CA CA002157288A patent/CA2157288C/fr not_active Expired - Lifetime
- 1994-02-24 CA CA002342974A patent/CA2342974C/fr not_active Expired - Lifetime
- 1994-02-24 CA CA2512926A patent/CA2512926C/fr not_active Expired - Lifetime
- 1994-02-24 EP EP02011928A patent/EP1264597B1/fr not_active Revoked
- 1994-02-24 NZ NZ535670A patent/NZ535670A/en not_active IP Right Cessation
- 1994-02-24 NZ NZ336527A patent/NZ336527A/en not_active IP Right Cessation
- 1994-02-24 DE DE122008000044C patent/DE122008000044I2/de active Active
- 1994-02-24 PT PT94909773T patent/PT688211E/pt unknown
- 1994-02-24 AT AT02011928T patent/ATE304356T1/de not_active IP Right Cessation
- 1994-02-24 KR KR1019950703700A patent/KR100506043B1/ko not_active Expired - Fee Related
- 1994-02-24 EP EP94909773A patent/EP0688211B1/fr not_active Expired - Lifetime
- 1994-02-24 AT AT94909773T patent/ATE218865T1/de active
- 1994-03-01 PE PE1994237564A patent/PE10095A1/es not_active Application Discontinuation
- 1994-03-01 BR BR9400764A patent/BR9400764A/pt not_active Application Discontinuation
- 1994-03-01 CO CO94008093A patent/CO4230017A1/es unknown
1995
- 1995-01-13 US US08/371,987 patent/US5593990A/en not_active Expired - Lifetime
- 1995-06-06 US US08/468,792 patent/US5712291A/en not_active Ceased
1997
- 1997-08-22 US US08/918,610 patent/US6235756B1/en not_active Expired - Lifetime
- 1997-10-16 US US08/950,673 patent/US6071948A/en not_active Expired - Lifetime
2000
- 2000-04-07 US US09/545,139 patent/US6469045B1/en not_active Expired - Fee Related
- 2000-11-09 US US09/710,533 patent/US6420414B1/en not_active Expired - Lifetime
2001
- 2001-02-26 JP JP2001050214A patent/JP4065373B2/ja not_active Expired - Lifetime
- 2001-07-05 US US09/899,318 patent/US20010056113A1/en not_active Abandoned
- 2001-09-28 US US09/966,895 patent/US20020049231A1/en not_active Abandoned
- 2001-10-24 US US10/001,183 patent/US20020119956A1/en not_active Abandoned
- 2001-12-12 US US10/015,252 patent/US20020052398A1/en not_active Abandoned
- 2001-12-19 US US10/026,037 patent/US6977268B2/en not_active Expired - Fee Related
- 2001-12-20 US US10/026,291 patent/US20020061911A1/en not_active Abandoned
2002
- 2002-06-11 US US10/167,531 patent/US20020161024A1/en not_active Abandoned
- 2002-12-13 US US10/319,389 patent/US20030187024A1/en not_active Abandoned
2003
- 2003-01-14 US US10/341,928 patent/US20030176463A1/en not_active Abandoned
2004
- 2004-07-28 JP JP2004220584A patent/JP2004359693A/ja active Pending
2005
- 2005-03-31 US US11/096,155 patent/US7723361B2/en not_active Expired - Fee Related
2006
- 2006-09-22 US US11/525,346 patent/US8012996B2/en not_active Expired - Fee Related
2007
- 2007-11-07 JP JP2007289175A patent/JP2008088182A/ja active Pending
2008
- 2008-08-01 FR FR08C0036C patent/FR08C0036I2/fr active Active
- 2008-08-20 LU LU91471C patent/LU91471I2/fr unknown
- 2008-09-01 NL NL300358C patent/NL300358I2/nl unknown

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002506861A (ja) *	1998-03-16	2002-03-05	コルジーンコーポレイション	２−（２，６−ジオキソピペリジン−３−イル）イソインドリン誘導体、その製剤および炎症性サイトカイン阻害剤としてのその使用
JP2011042674A (ja) *	1998-03-16	2011-03-03	Celgene Corp	２−（２，６−ジオキソピペリジン−３−イル）イソインドリン誘導体、その製剤および炎症性サイトカイン阻害剤としてのその使用
JP2002514578A (ja) *	1998-05-11	2002-05-21	エントレメッドインコーポレイテッド	２−フタルイミジノグルタル酸の類似体および血管新生の阻害剤としてのそれらの使用
JP2004538322A (ja) *	2001-08-06	2004-12-24	ザチルドレンズメディカルセンターコーポレイション	窒素置換サリドマイド誘導体の合成及び抗腫瘍活性
JP2009509945A (ja) *	2005-09-27	2009-03-12	天津和美生物技▲術▼有限公司	細胞の腫瘍壊死因子の放出を抑制できる５Ｈ−チエノ［３，４−ｃ］ピロール−４，６ジオン誘導物
JP2009538318A (ja) *	2006-05-26	2009-11-05	セルジーン・コーポレーション	併用療法において免疫調節化合物を用いる方法及び組成物

Also Published As

Publication number	Publication date
JP2001278789A (ja)	2001-10-10
CA2342974C (fr)	2005-08-16
US5712291A (en)	1998-01-27
DE122008000044I1 (fr)	2009-01-02
ATE218865T1 (de)	2002-06-15
AU676722B2 (en)	1997-03-20
JP4065373B2 (ja)	2008-03-26
DK1264597T3 (da)	2006-01-16
FR08C0036I2 (fr)	2009-11-20
ES2174873T3 (es)	2002-11-16
NZ262676A (en)	1999-08-30
DE69434490D1 (de)	2005-10-20
EP1245229A2 (fr)	2002-10-02
US20030176463A1 (en)	2003-09-18
US20020061911A1 (en)	2002-05-23
EP1264597B1 (fr)	2005-09-14
AU676722C (en)	1994-09-26
US20010056113A1 (en)	2001-12-27
US8012996B2 (en)	2011-09-06
HK1052865A1 (en)	2003-10-03
DE122008000044I2 (fr)	2010-12-30
US6469045B1 (en)	2002-10-22
ES2245711T3 (es)	2006-01-16
KR960701632A (ko)	1996-03-28
US20020161024A1 (en)	2002-10-31
US20020119956A1 (en)	2002-08-29
EP1537870A2 (fr)	2005-06-08
NZ535670A (en)	2006-05-26
KR100506043B1 (ko)	2005-11-08
DE69434490T2 (de)	2006-06-22
CA2512926C (fr)	2010-08-03
PE10095A1 (es)	1995-04-25
DK0688211T3 (da)	2002-09-23
LU91471I2 (fr)	2008-11-06
CO4230017A1 (es)	1995-10-19
EP1264597A3 (fr)	2003-03-19
FR08C0036I1 (fr)	2008-10-17
US20030187024A1 (en)	2003-10-02
CA2157288A1 (fr)	1994-09-15
ATE304356T1 (de)	2005-09-15
US6420414B1 (en)	2002-07-16
NL300358I1 (nl)	2008-11-03
JP2008088182A (ja)	2008-04-17
EP1264597A2 (fr)	2002-12-11
CA2342974A1 (fr)	1994-09-15
US20050215593A1 (en)	2005-09-29
US20070021464A1 (en)	2007-01-25
US7723361B2 (en)	2010-05-25
EP0688211A4 (fr)	1997-05-21
NL300358I2 (nl)	2009-06-02
US6977268B2 (en)	2005-12-20
US20020052398A1 (en)	2002-05-02
US5629327A (en)	1997-05-13
DE69430796T2 (de)	2003-01-30
DE69430796D1 (de)	2002-07-18
CA2512926A1 (fr)	1994-09-15
AU6248694A (en)	1994-09-26
US6071948A (en)	2000-06-06
WO1994020085A1 (fr)	1994-09-15
BR9400764A (pt)	1994-11-01
NZ336527A (en)	2005-01-28
NZ535671A (en)	2006-05-26
EP0688211B1 (fr)	2002-06-12
PT688211E (pt)	2002-11-29
US20020049231A1 (en)	2002-04-25
EP1245229A3 (fr)	2004-05-06
US20020061923A1 (en)	2002-05-23
EP0688211A1 (fr)	1995-12-27
CA2157288C (fr)	2005-11-08
US6235756B1 (en)	2001-05-22
US5593990A (en)	1997-01-14
EP1537870A3 (fr)	2007-12-12
JP2004359693A (ja)	2004-12-24

Legal Events

Date	Code	Title	Description
2004-11-11	RD02	Notification of acceptance of power of attorney	Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20041022
2004-11-11	RD04	Notification of resignation of power of attorney	Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20041022
2005-08-23	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050823
2005-12-08	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051117
2006-01-06	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060106
2006-06-05	A313	Final decision of rejection without a dissenting response from the applicant	Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20060525
2006-06-06	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060606
2006-09-14	A761	Written withdrawal of application	Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20060825

Publication	Publication Date	Title
JPH08507767A (ja)	1996-08-20	管脈形成を抑制する方法および組成物
JP5066505B2 (ja)	2012-11-07	血管形成抑制のための方法と組成物
USRE40360E1 (en)	2008-06-03	Methods for inhibition of angiogenesis with a composition comprising 3-hydroxythalidomide
US6518298B2 (en)	2003-02-11	Methods and compositions for inhibition of angiogenesis with EM-138
US20010056114A1 (en)	2001-12-27	Methods for the inhibition of angiogenesis with 3-amino thalidomide
US20120142734A1 (en)	2012-06-07	Methods for treating tumors with thalidomide
HK1077516A (en)	2006-02-17	Methods and compositions for treating cancer